NCT05009797 PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation
| NCT ID | NCT05009797 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Lille |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 750 participants |
| Start Date | 2023-02-16 |
| Primary Completion | 2031-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 750 participants in total. It began in 2023-02-16 with a primary completion date of 2031-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood. The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation. The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.
Eligibility Criteria
Inclusion Criteria: * Patient undergoing atrial fibrillation catheter ablation * Able to give their consent Exclusion Criteria: * Childs * Patient under guardianship * Patients unable to give their consent * Pregnancy
Contact & Investigator
Sandro Ninni, MD
PRINCIPAL INVESTIGATOR
University Hospital, Lille
Frequently Asked Questions
Who can join the NCT05009797 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05009797 currently recruiting?
Yes, NCT05009797 is actively recruiting participants. Contact the research team at sandro.ninni@chru-lille.fr for enrollment information.
Where is the NCT05009797 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT05009797 clinical trial?
NCT05009797 is sponsored by University Hospital, Lille. The principal investigator is Sandro Ninni, MD at University Hospital, Lille. The trial plans to enroll 750 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.